Summary of COVID-19 alunacedase alfa studies

1. Bundgaard et al., Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

185 patient alunacedase alfa late treatment RCT: 31% higher mortality (p=0.61) and 23% lower ventilation (p=0.64).
RCT 181 hospitalized COVID-19 patients showing no significant improvement with alunacedase alfa.
Dec 2020, NCT04335136, https://clinicaltrials.gov/study/NCT04335136, https://c19p.org/bundgaard2